1.   Klibanski A, Adams-Campbell L, Bassford T et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6):785-795.
2.   US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004.
3.   World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: WHO, 1994.
4.   Baim S, Binkley N, Bilezikian JP et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11(1):75-91.
5.   Lewiecki EM, Binkley N, Petak SM. DXA Quality Matters. J Clin Densitom 2006; 9(4):388-392.
6.   National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
7.   Qaseem A, Snow V, Shekelle P, Hopkins R, Jr., Forciea MA, Owens DK. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148(9):680-684.
8.   Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19(10):1395-1408.
9.   Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19(4):399-428.
10.   Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312(7041):1254-1259.
11.   Wainwright SA, Marshall LM, Ensrud KE et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90(5):2787-2793.
12.   Lewiecki EM, Laster AJ. Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry. J Clin Endocrinol Metab 2006; 91(11):4215-4222.
13.   Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8(9):1137-1148.
14.   Schousboe JT, DeBold CR. Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice. Osteoporos Int 2006; 17(2):281-289.
15.   Lewiecki EM. Update on bone density testing. Curr Osteoporos Rep 2005; 3(4):136-142.
16.   Lotz JC, Cheal EJ, Hayes WC. Fracture prediction for the proximal femur using finite element models: Part I--Linear analysis. J Biomechan Eng 1991; 113:353-360.
17.   Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. Endocr Rev 2002; 23(4):497-507.
18.   Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85(1):231-236.
19.   Mazess R, Chesnut CH, III, McClung M, Genant H. Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int 1992; 51(1):14-17.
20.   Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK. Radiation exposure in bone mineral density assessment. [Review] [86 refs]. Applied Radiation & Isotopes 1999; 50(1):215-236.
21.   Hans DB, Shepherd JA, Schwartz EN et al. Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008; 11(1):188-206.
22.   Bonnick SL. Bone densitometry in clinical practice- application and interpretation. 2nd ed ed. Totowa, N.J: Humana Press, 2004.
23.   Lewiecki EM, Richmond B, Miller PD. Uses and misuses of quantitative ultrasonography in managing osteoporosis. Cleve Clin J Med 2006; 73(8):742-752.
24.   Engelke K, Adams JE, Armbrecht G et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom 2008; 11(1):123-162.
25.   Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom 1999; 2:343-350.
26.   Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18(8):1033-1046.
27.   Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield, 2007.
28.   WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 
29.   National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003.
30.   National Osteoporosis Foundation, International Society for Clinical Densitometry. Recommendations to DXA Manufacturers for FRAX® Implementation. National Osteoporosis Foundation .
31.   Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 2010; Epub.
32.   Vogt TM, Ross PD, Palermo L et al. Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures. Fracture Intervention Trial Research Group. Mayo Clin Proc 2000; 75(9):888-896.
33.   Gunnes M, Lehmann EH, Mellstrom D, Johnell O. The relationship between anthropometric measurements and fractures in women. Bone 1996; 19(4):407-413.
34.   Siminoski K, Jiang G, Adachi JD et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int 2005; 16(4):403-410.
35.   Margolis KL, Ensrud KE, Schreiner PJ, Tabor HK. Body size and risk for clinical fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 2000; 133(2):123-127.
36.   De Laet C, Kanis JA, Oden A et al. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int 2005.
37.   Ensrud KE, Ewing SK, Stone KL et al. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc 2003; 51(12):1740-1747.
38.   Holick MF, Siris ES, Binkley N et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90(6):3215-3224.
39.   Tannenbaum C, Clark J, Schwartzman K et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2003; 87:4431-4437.
40.   Wagman RB, Marcus R. Beyond bone mineral density-navigating the laboratory assessment of patients with osteoporosis. J Clin Endocrinol Metab 2002; 87(10):4429-4430.
41.   Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab 2003; 88(3):1404-1405.
42.   Luckey MM, Tannenbaum C. Authors' response: Recommended testing in patients with low bone density. J Clin Endocrinol Metab 2003; 88(3):1405.
43.   Harper KD, Weber TJ. Secondary osteoporosis - Diagnostic considerations. Endocrinol Metabol Clin North Am 1998; 27(2):325-348.
44.   Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338(11):736-746.
45.   Favus MJ. Postmenopausal osteoporosis and the detection of so-called secondary causes of low bone density. J Clin Endocrinol Metab 2005; 90(6):3800-3801.
46.   Looker AC, Orwoll ES, Johnston CCJr et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12:1761-1768.
47.   Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16:87-116.
48.   Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer 2005; 93 Suppl 1:S16-S22.
49.   Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58(2 Suppl 1):101-107.
50.   Melton LJ, III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005; 20(3):487-493.
51.   De Prisco C, Levine SN. Metabolic bone disease after gastric bypass surgery for obesity. Am J Med Sci 2005; 329(2):57-61.
52.   Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Osteoporosis after gastrectomy: bone mineral density of lumbar spine assessed by dual-energy X-ray absorptiometry. Calcif Tissue Int 2000; 66(2):119-122.
53.   Cormier C, Souberbielle JC, Kahan A. Primary hyperparathyroidism and osteoporosis in 2004. Joint Bone Spine 2004; 71(3):183-189.
54.   Földes J, Tarján G, Szathmari M, Varga F, Krasznai I, Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism:  Is this thyroid status a risk factor for osteoporosis. Clin Endocrinol (Oxf ) 1993; 39:521-527.
55.   Mancini T, Doga M, Mazziotti G, Giustina A. Cushing's Syndrome and Bone. Pituitary 2004; 7:249-252.
56.   Bianchi ML, Bardella MT. Bone and celiac disease. Calcif Tissue Int 2002; 71(6):465-471.
57.   Freitag A, Barzel US. Differential diagnosis of osteoporosis. Gerontology 2002; 48(2):98-102.
58.   Orlic ZC, Raisz LG. Causes of secondary osteoporosis. J Clin Densitom 1999; 2(1):79-92.
59.   Binkley N, Krueger D, Cowgill CS et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004; 89(7):3152-3157.
60.   Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1):31-41.
61.   Heaney RP, Recker RR, Ryan RA. Urinary calcium in perimenopausal women: normative values. Osteoporos Int 1999; 9(1):13-18.
62.   Audran M, Legrand E. Hypercalciuria. Joint Bone Spine 2000; 67(6):509-515.
63.   Pak CY, Kaplan R, Bone H, Townsend J, Waters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med 1975; 292(10):497-500.
64.   Pacifici R. Idiopathic hypercalciuria and osteoporosis--distinct clinical manifestations of increased cytokine-induced bone resorption? J Clin Endocrinol Metab 1997; 82(1):29-31.
65.   Fasano A, Berti I, Gerarduzzi T et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163(3):286-292.
66.   Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 2005; 142(4):289-298.
67.   McLean RR, Jacques PF, Selhub J et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350(20):2042-2049.
68.   van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350(20):2033-2041.
69.   Chines A, Pacifici R, Avioli LV, Teitelbaum SL, Korenblat PE. Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. J Clin Endocrinol Metab 1991; 72(1):140-144.
70.   Lidor C, Frisch B, Gazit D, Gepstein R, Hallel T, Mekori YA. Osteoporosis as the sole presentation of bone marrow mastocytosis. J Bone Miner Res 1990; 5(8):871-876.
71.   Weger M, Deutschmann H, Weger W, Kotanko P, Skrabal F. Incomplete renal tubular acidosis in 'primary' osteoporosis. Osteoporos Int 1999; 10(4):325-329.
72.   Bergmann P, Body JJ, Boonen S et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009; 63(1):19-26.
73.   Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13:1431-1438.
74.   Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87(4):1586-1592.
75.   Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18:1051-1056.
76.   Bauer DC, Black DM, Garnero P et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19(8):1250-1258.
77.   Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19(3):394-401.
78.   Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 2008; 23(8):1155-1167.
79.   Chen P, Satterwhite JH, Licata AA et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20(6):962-970.
80.   Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000; 11 Suppl 6:S30-S44.
81.   Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005; 26(4):97-122.
82.   Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001; 47(8):1443-1450.
83.   Srivastava AK, Vliet EL, Lewiecki EM et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005; 21(7):1015-1026.
84.   Nishizawa Y, Nakamura T, Ohta H et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 2005; 23(2):97-104.
85.   Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008; 19(10):1363-1368.
86.   Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89(3):1117-1123.
87.   Meier C, Seibel MJ, Kraenzlin ME. Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 2009; 24(3):386-388.
88.   Lewiecki EM, Baim S, Bilezikian JP, Eastell R, LeBoff MS, Miller PD. 2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom 2009; 12(2):135-157.
89.   Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008; 75(10):739-750.
90.   Schousboe JT, Vokes T, Broy SB et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom 2008; 11(1):92-108.